Increased risk of gastrointestinal adverse effects under SSRI/NSAID combination may be due to pharmacokinetic interactions.
Zullino
Daniele Fabio
DF
Khazaal
Yasser
Y
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects*; D001189:Aryl Hydrocarbon Hydroxylases / Q000037:antagonists & inhibitors; D065729:Cytochrome P-450 CYP2C9; D004338:Drug Combinations; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D006801:Humans; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000929:Antidepressive Agents, Tricyclic; D001189:Aryl Hydrocarbon Hydroxylases; D065729:Cytochrome P-450 CYP2C9; D004338:Drug Combinations; D017367:Selective Serotonin Reuptake Inhibitors; C450260:CYP2C9 protein, human